You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Express Scripts
McKinsey
McKesson
Medtronic

Last Updated: February 23, 2024

Lonafarnib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for lonafarnib and what is the scope of freedom to operate?

Lonafarnib is the generic ingredient in one branded drug marketed by Eiger Biopharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lonafarnib has nine patent family members in six countries.

One supplier is listed for this compound.

Summary for lonafarnib
International Patents:9
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 73
Clinical Trials: 32
Patent Applications: 4,305
What excipients (inactive ingredients) are in lonafarnib?lonafarnib excipients list
DailyMed Link:lonafarnib at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lonafarnib
Generic Entry Date for lonafarnib*:
Constraining patent/regulatory exclusivity:
TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lonafarnib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Soroka University Medical CenterPhase 3
Eiger BioPharmaceuticalsPhase 3
Boston Children’s HospitalPhase 1/Phase 2

See all lonafarnib clinical trials

US Patents and Regulatory Information for lonafarnib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-001 Nov 20, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eiger Biopharms ZOKINVY lonafarnib CAPSULE;ORAL 213969-002 Nov 20, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for lonafarnib

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
EigerBio Europe Limited Zokinvy lonafarnib EMEA/H/C/005271
Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.
Authorised no no yes 2022-07-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for lonafarnib

Country Patent Number Title Estimated Expiration
Canada 2501464 GENE LMNA ET SON IMPLICATION DANS LE SYNDROME D'HUTCHINSON-GILFOR D ET L'ARTERIOSCLEROSE (LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIASYNDROME (HGPS) AND ARTERIOSCLEROSIS) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2006081444 ⤷  Try a Trial
Austria 547536 ⤷  Try a Trial
Japan 4436800 ⤷  Try a Trial
European Patent Office 1853265 INHIBITEURS DE FARNESYL TRANSFERASE DESTINES A TRAITER LES LAMINOPATHIES, LE VIEILLISSEMENT CELLULAIRE ET L'ATHEROSCLEROSE (FARNESYLTRANSFERASE INHIBITORS FOR USE IN THE TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS) ⤷  Try a Trial
Japan 2006507845 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.